Case Reports Archives

Two case reports of resensitization to previous chemotherapy with the novel hypoxia-activated hypomethylating anticancer agent RRx-001 in metastatic colorectal cancer patients

Oct 29, 2021

Reid T, Dad S, Korn R, Oronsky B, Knox S, Scicinski J. Case Rep Oncol. 2014 Jan 24;7(1):79-85. doi: 10.1159/000358382.

Dysphonia after bevacizumab rechallenge: A case report.

Oct 29, 2021

Carter C, Caroen S, Oronsky A, Oronsky B. Case Rep Oncol. 2015 Oct 14;8(3):423-5. doi: 10.1159/000441122. eCollection 2015 Sep-Dec.

$Flushing out carcinoid syndrome: Beneficial effect of the anticancer epigenetic agent RRx-001 in a patient with a treatment-refractory neuroendocrine tumor$

Flushing out carcinoid syndrome: Beneficial effect of the anticancer epigenetic agent RRx-001 in a patient with a treatment-refractory neuroendocrine tumor

Oct 29, 2021

Carter C, Degesys A, Oronsky B, Scicinski J, Caroen S, Oronsky A, Reid T, Cabrales P, Roswarski J. Case Rep Oncol. 2015 Oct 30;8(3):461-5.

RRx-001-induced tumor necrosis and immune cell Infiltration in an EGFR mutation-positive NSCLC with resistance to EGFR tyrosine kinase inhibitors: A case report

Oct 29, 2021

Brzezniak C, Schmitz B, Peterson P, Degesys A, Oronsky B, Scicinski J, Caroen S, Carter C. Case Rep Oncol. 2016 Jan 15;9(1):45-50.

The case of a zebra that was misdiagnosed as a horse: Pulmonary tumor thrombotic microangiopathy, a new paraneoplastic syndrome, mimicking PD-1-Induced pneumonitis

Oct 29, 2021

Carter C, Browning R, Oronsky B, Scicinski J, Brzezniak C. Case Rep Oncol. 2016 Jan 27;9(1):68-75.

$Partial response to platinum doublets in refractory EGFR-positive non-small cell lung cancer patients after RRx-001: Evidence of episensitization$

Partial response to platinum doublets in refractory EGFR-positive non-small cell lung cancer patients after RRx-001: Evidence of episensitization

Oct 29, 2021

Carter C, Oronsky B, Caroen S, Scicinski J, Cabrales P, Reid T, Degesys A, Jenkins J, Brzezniak C. Case Rep Oncol. 2016 Jan 28;9(1):62-7.

Immune reactivity and pseudoprogression or tumor flare in a serially biopsied neuroendocrine patient treated with the epigenetic agent RRx-001

Oct 29, 2021

Carter C, Schmitz B, Peterson P, Quinn M, Degesys A, Jenkins J, Oronsky B, Scicinski J, Caroen S, Reid T, Cabrales P, Brzezniak C. Case Rep Oncol. 2016 Mar 10;9(1):164-70.

$RRx-001 in refractory small-cell lung carcinoma: A case report of a partial response after a third reintroduction of platinum doublets.$

RRx-001 in refractory small-cell lung carcinoma: A case report of a partial response after a third reintroduction of platinum doublets.

Oct 29, 2021

Carter C, Oronsky B, Caroen S, Scicinski J, Degesys A, Kim M, Oronsky A, Lybeck H, Cabrales P, Oronsky N, Reid T, Roswarski J, Brzezniak C. Case Rep Oncol. 2016 Mar 11;9(1):171-6. doi: 10.1159/000444631. eCollection 2016 Jan-Apr.

Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases

Oct 29, 2021

Kim M, Parmar H, Cao Y, Knox S, Oronsky B, Scicinski J, Lawrence T, Lao C. Neuro Oncol. 2016 Mar;18(3):455-6.

Whole brain radiotherapy and RRx-001: Two partial responses in radioresistant melanoma brain metastases from a phase I/II clinical trial: A TITE-CRM phase I/II clinical trial

Oct 29, 2021

Kim M, Parmar H, Cao Y, Pramanik P, Schipper M, Hayman J, Junck L, Mammoser A, Heth J, Carter C, Oronsky A, Knox S, Caroen S, Oronsky B, Scicinski J, Lawrence T, Lao C. Transl Oncol. 2016 Apr;9(2):108-13.

Pulmonary tumor thrombotic microangiopathy: A new paraneoplastic syndrome?

Oct 29, 2021

Carter C, Scicinski J, Lybeck H, Oronsky B. Case Rep Oncol. 2016 Apr 23;9(1):246-8.

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC

Oct 29, 2021

Carter C, Oronsky B, Caroen S, Scicinski J, Cabrales P, Degesys A, Brzezniak C. Respir Med Case Rep. 2016 Apr 24;18:62-5.

$Partial response in an RRx-001 primed patient with refractory small-cell lung cancer after a third introduction of platinum doublets.$

Partial response in an RRx-001 primed patient with refractory small-cell lung cancer after a third introduction of platinum doublets.

Oct 29, 2021

Carter C, Oronsky B, Caroen S, Scicinski J, Degesys A, Cabrales P, Reid T, Brzezniak C. Case Rep Oncol. 2016 May 24;9(2):285-9. doi: 10.1159/000446209. eCollection 2016 May-Aug.

Conversion of platinum-etoposide-resistant to sensitive SCLC after treatment with the epi-immunotherapeutic RRx-001: A case report.

Oct 29, 2021

Brzezniak C, Oronsky B, Scicinski J, Caroen S, Cabrales P, Dean Abrouk N, Kim M, Brown J, Reid T, Larson C, Oronsky A, Day R, Degesys A, Carter C. Oncol Res Treat. 2016;39(11):720-723. Epub 2016 Sep 19.

A partial response to reintroduced chemotherapy in a resistant small cell lung cancer patient after priming with RRx-001.

Oct 29, 2021

Oronsky B, Caroen S, Zeman K, Quinn M, Brzezniak C, Scicinski J, Cabrales P, Reid T, Trepel J, Abrouk N, Larson C, Oronsky A, Lybeck H, Day R, Carter C. Clin Med Insights Oncol. 2016 Nov 6;10:105-108. eCollection 2016.

RRx-001 priming of PD-1 inhibition in the treatment of small cell carcinoma of the vagina: A rare gynecological tumor.

Oct 29, 2021

Brzezniak C, Oronsky B, Trepel J, Summers T Jr, Cabrales P, Lee M, Day R, Jha S, Caroen S, Zeman K, Ferry L, Harmer C, Oronsky N, Lybeck M, Lybeck H, Brown J, Reid T, Carter C. Case Rep Oncol. 2017 Mar 29;10(1):276-280. doi: 10.1159/000464101. eCollection 2017 Jan-Apr.

A complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets.

Oct 29, 2021

Brzezniak C, Oronsky B, Aggarwal R. Eur Urol. 2018 Feb;73(2):306-307. doi: 10.1016/j.eururo.2017.09.010. Epub 2017 Sep 21.

$A recurrent platinum refractory ovarian cancer patient with a partial response after RRx-001 resensitization to platinum doublet$

A recurrent platinum refractory ovarian cancer patient with a partial response after RRx-001 resensitization to platinum doublet

Oct 29, 2021

Cottrill H, Cason S, Caroen S, Oronsky B, Donaldson E. J Investig Med High Impact Case Rep. 2018 Mar 7.

Abscopal benefit of surgery in 3 immunotherapy-treated patients with unresectable cancer

Oct 29, 2021

Oronsky B, Larson C, Reid T, Carter C. Journal of Investigative Medicine High Impact Case Reports, July 6, 2018.

Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets

Oct 29, 2021

Ojemuyiwa M, Zeman K, Spira A, Oronsky B, Ray C, Trepel, JB, Lee MJ, Onyiuke I, Brzezniak C Clinical Case Reports, In Press. 2018